Faron Pharmaceuticals Oy Grant of options (6156P)
November 21 2016 - 2:01AM
UK Regulatory
TIDMFARN
RNS Number : 6156P
Faron Pharmaceuticals Oy
21 November 2016
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Grant of options
TURKU - FINLAND, 21 November 2016 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, announces that on 18 November 2016 the Board of Faron
granted 400,000 options over ordinary shares in the Company
("Options") under the Faron 2015 Option Plan at an exercise price
of 290 euro cents per share. The options are exercisable between 8
October 2016 and 30 September 2021. The details of the 2015 Option
Plan are described in the AIM Admission Document dated 11 November
2015, which is available on Company's website.
The granted 400,000 options represent 1.49% of the fully-diluted
Ordinary Share Capital of the Company.
Included in the number of options granted on 18 November 2016,
the following options were issued to Directors and other Persons
Discharging Managerial Responsibility ("PDMRs"):
Director Options granted
Frank Armstrong 40,000
Matti Manner 20,000
Markku Jalkanen 80,000
Yrjö E K Wichmann 30,000
Juho Jalkanen 20,000
Jonathan Knowles 20,000
Huaizheng Peng 20,000
Leopoldo Zambeletti 20,000
Total directors 250,000
PDMRs
Ilse Piippo 37 400
Mikael Maksimow 28 100
Matti Karvonen 28 100
Total PDMRs 93 600
For more information please contact:
Faron Pharmaceuticals Ltd
Katja Wallenlind
Phone +358 (50) 577 4807
E-mail: katja.wallenlind@faronpharmaceuticals.com
Hume Brophy, PR
Mary Clark, Eva Haas, Hollie Vile
Phone: +44 207 862 6390
E-mail: faron@humebrophy.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson, Rebecca Anderson
Phone: +44 207 213 0880
Panmure Gordon (UK) Limited, Joint Broker
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker
Ranald McGregor-Smith, Francis North
Phone: +44 207 659 1234
About Faron Pharmaceuticals Ltd
Faron is a clinical stage biopharmaceutical company developing
novel treatments for medical conditions with significant unmet
needs. The Company currently has a pipeline focusing on acute organ
traumas, cancer immunotherapy and vascular damage. The pipeline is
built on Faron's scientific knowledge and control of the
endothelial barrier, the membrane of cells lining blood and
lymphatic vessels to separate blood content from tissues. The
Company's lead candidate Traumakine(R) is in development for the
treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare,
severe, life-threatening medical condition characterised by
widespread inflammation in the lungs. Traumakine is currently in
pan-European (INTEREST) and Japanese pivotal Phase III studies.
Additionally, Faron is developing Clevegen(R) a ground breaking
pre-clinical anti-Clever-1 antibody. Clevegen has the ability to
convert the immune environment around a tumour from being immune
suppressive to immune stimulating. This novel macrophage-directed
immuno-oncology approach is called Tumour Immunity Enabling
Technology ("TIET") and can be used alone or in combination with
other immune checkpoint molecules for the treatment of cancer
patients. New application opportunities related to TIET cover
chronic infections and inefficient vaccination. Based in Turku,
Finland, Faron Pharmaceuticals is listed on AIM under the ticker
'FARN'. Further information is available at
www.faronpharmaceuticals.com
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
--------------------------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
---- --------------------------------------------------------------------------------------
a. Name(s) 1. Dr Markku Jalkanen
2. Dr Frank Armstrong
3. Matti Manner
4. Dr Juho Jalkanen
5. Yrjö Wichmann
6. Leopoldo Zambeletti
7. Dr Huaizheng Peng
8. Professor Jonathan Knowles
----------------------------------------------------------
2 Reason for notification
---- -------------------------- ----------------------------------------------------------
a. Position/Status Directors of the Company
---- -------------------------- ----------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
---- -------------------------- ----------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
---- -------------------------- ----------------------------------------------------------
b. LEI 7437009H31TO1DC0EB42
---- -------------------------- ----------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- --------------------------------------------------------------------------------------
a. Description of Options over ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
---- -------------------------- ----------------------------------------------------------
b. Nature of the Grant of Options to subscribe for Ordinary
transaction Shares
---- -------------------------- ----------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------- ------------------ -----------
1. EUR2.90 80,000
2. EUR2.90 40,000
3. EUR2.90 20,000
4. EUR2.90 20,000
5. EUR2.90 30,000
6. EUR2.90 20,000
7. EUR2.90 20,000
8. EUR2.90 20,000
------------------ -----------
Aggregated information
- Aggregated Volume
d. - Price 250,000
---- -------------------------- ----------------------------------------------------------
e. Date of the transaction 18 November 2016
---- -------------------------- ----------------------------------------------------------
f. Place of the transaction Turku
---- -------------------------- ----------------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
--------------------------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
---- --------------------------------------------------------------------------------------
a. Name 1. Ilse Piippo
2. Mikael Mksimow
3. Matti Karvonen
----------------------------------------------------------
2 Reason for notification
---- -------------------------- ----------------------------------------------------------
a. Position/Status Person discharging managerial responsibilities
---- -------------------------- ----------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
---- -------------------------- ----------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
---- -------------------------- ----------------------------------------------------------
b. LEI 7437009H31TO1DC0EB42
---- -------------------------- ----------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- --------------------------------------------------------------------------------------
a. Description of Options over ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
---- -------------------------- ----------------------------------------------------------
b. Nature of the Grant of Options to subscribe for Ordinary
transaction Shares
---- -------------------------- ----------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------- ------------------ -----------
1. EUR2.90 37,400
2. EUR2.90 28,100
3. EUR2.90 28,100
------------------ -----------
Aggregated information
- Aggregated Volume
d. - Price 93,600
---- -------------------------- ----------------------------------------------------------
e. Date of the transaction 18 November 2016
---- -------------------------- ----------------------------------------------------------
f. Place of the transaction Turku
---- -------------------------- ----------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAKFDQPBDDKDD
(END) Dow Jones Newswires
November 21, 2016 02:00 ET (07:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024